AlphAIAlphAI — Financial news for AI agents
SEC EDGARMAY 271 min read$THC

HANEY CECIL D sold (to issuer) $86K of THC

HANEY CECIL D sold (to issuer) 493 shares of TENET HEALTHCARE CORP (THC) at $173.78 on 2026-05-22.

Original reporting
SEC EDGAR · HANEY CECIL D
Published May 27, 2026, 12:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI May 27, 2026, 12:01 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$THC
Neutral
medium confidence
Mentioned
$THC
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$THCNeutralLow
01

Why it matters

The disclosure updates insider ownership but does not include any operational, regulatory, or financial developments for Tenet Healthcare.

02

Market read

Traders may briefly reassess sentiment around THC due to insider selling, but the event lacks fundamental catalysts.

03

What to watch

No 10b5-1 plan is cited, but the transaction code D (sale to issuer) can still be non-informational; watch for subsequent insider buys/sales or larger institutional changes.

Relevance 6/10Timing: Filing dated 2026-05-26 for a transaction on 2026-05-22; impact, if any, is most relevant around the filing window.

Background

SEC Form 4 discloses insider transactions; code D indicates sale to the issuer (e.g., buyback participation).

Company-level read

Ticker impact

$THCNeutralMedium confidence
Context

Tenet Healthcare director Haney Cecil D sold 493 shares to the issuer for about $85.7K at $173.78/share, per SEC Form 4.

Expected impact

Limited near-term impact; any reaction is likely small and short-lived unless follow-on filings show broader selling.

Evidence & confidence

Single director transaction size is small versus typical market moves, and the filing provides no new company-specific operating or financial information.

Market effects

Sector

No clear read-through to healthcare sector fundamentals from a single director Form 4 sale.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Because the sale is to the issuer (often tied to buyback/plan mechanics), it may reflect routine liquidity or corporate action rather than bearish expectations.

Key entities

  • issuer
    Tenet Healthcare Corp

    Company whose director insider transaction was reported on SEC Form 4.

  • director
    Haney Cecil D

    Tenet Healthcare director who sold 493 shares to the issuer on 2026-05-22.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

THC insider trading history →

Related articles

OCT 5
$THCMed

Tenet Healthcare (THC) Refinances Debt On A Fair Value Story That Looks Tightly Priced

Tenet Healthcare (THC) issued $2b in 6.250% senior notes due 2034 to refinance existing debt. Its share price has risen 25.4% in 90 days and 29.7% year-to-date. The company's fair value is estimated at $260, slightly above its current price of $258.62. Management's cost-reduction efforts have lowered contract labor and certain analytics costs, but further margin expansion may be limited.

simplywall.st2 min
SEP 30
$THCMed

Can THC's Cash Flow Support Its Expanding Capital-Return Strategy?

Tenet Healthcare (THC) reported a 27.1% year-over-year increase in operating cash flow to $2.2B in H1 2026, raising its adjusted free cash flow guidance to $1.825B-$2.055B. The company spent $1.4B on share buybacks and increased its repurchase authorization by $2B. THC is balancing buybacks with growth investments, expecting $700M-$800M in capital spending. Peers UHS and HCA also reported significant buybacks and capital investments.

theglobeandmail.com2 min
SEP 26
$THCMed

Is Tenet Healthcare Corporation (THC) A Solid Play on Expanding Ambulatory Business?

Tenet Healthcare (THC) is focusing on its ambulatory business for growth, with BMO Capital Markets noting favorable long-term trends and margins. USPI, Tenet’s ambulatory platform, reported 9.3% revenue growth in Q2. BMO initiated coverage with a Market Perform rating and $265 price target. Hedge funds increased stakes, while short interest declined. Risks include reimbursement changes and competition.

insidermonkey.com3 min
SEP 20
$THCMedAI 8/10

What Tenet Healthcare (THC)'s $2 Billion Debt Refinance Means For Shareholders

Tenet Healthcare (THC) completed a $2 billion private placement of senior unsecured notes due 2034 at a 6.250% coupon. Proceeds will redeem $1.5 billion of 2027 secured notes and $0.5 billion of 2028 senior notes, altering its capital structure and interest obligations. Analysts project revenues of $24.1 billion and earnings of $1.6 billion by 2029, with some seeing potential upside.

simplywall.st3 min
SEP 9
$THCMedAI 8/10

What Tenet Healthcare (THC)'s $2b Debt Refinance Means For Shareholders

Tenet Healthcare (THC) priced a $2.0 billion private placement of 6.250% senior notes due 2034, upsized from $1.5 billion, to refinance existing 2027 and 2028 debt. The refinancing replaces secured and partly secured borrowings with unsecured notes, altering the company's debt structure. Investors focus on execution, pricing, and free cash flow, with high debt and earnings declines noted as risks.

simplywall.st2 min